Related Experiment Video
Updated: May 12, 2026

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice
Published on: April 19, 2011
Adenosine A3 receptor deficiency exerts unanticipated protective effects on the pressure-overloaded left ventricle
Zhongbing Lu1, John Fassett, Xin Xu
1Center for Vascular Biology, University of Minnesota, Minneapolis, MN 55455, USA.
Insights
Adenosine protects the heart, but A(3) receptors (A(3)R) counteract this effect. Blocking A(3)R may treat heart hypertrophy and dysfunction caused by pressure overload.
Area of Science:
- Cardiovascular Research
- Molecular Cardiology
- Pharmacology
Background:
- Endogenous adenosine offers cardioprotection against hypertrophy and heart failure.
- The specific roles of adenosine A(1) receptors (A(1)R) and A(3) receptors (A(3)R) in this process remain unclear.
Purpose of the Study:
- To investigate the contribution of A(1)R and A(3)R to cardiac protection during pressure overload.
- To determine if A(3)R gene deficiency (KO) or A(1)R KO impacts cardiac response to transverse aortic constriction (TAC).
Main Methods:
- Utilized A(3)R KO and A(1)R KO mouse models subjected to TAC.
- Assessed left ventricular hypertrophy, fibrosis, cardiac dysfunction, and myocardial stress markers.
- Examined effects in CD73 KO mice and phenylephrine-induced cardiomyocyte hypertrophy models.
- Investigated the impact of A(3)R antagonism on adenosine analogue efficacy.
Main Results:
- Contrary to hypothesis, A(3)R KO attenuated TAC-induced cardiac hypertrophy, fibrosis, and dysfunction.
- A(3)R KO reduced markers of myocardial stress and hypertrophy.
- A(1)R KO increased mortality post-TAC but did not affect hypertrophy or dysfunction.
- Impaired adenosine production (CD73 KO) exacerbated TAC effects; A(3)R antagonism enhanced cardioprotective effects of an adenosine analogue.
Conclusions:
- Adenosine provides cardiac protection, but A(3)R activity opposes this protective effect.
- Selective A(3)R attenuation presents a potential therapeutic strategy for pressure overload-induced cardiac hypertrophy and dysfunction.
Background:
Endogenous adenosine can protect the overloaded heart against the development of hypertrophy and heart failure, but the contribution of A(1) receptors (A(1)R) and A(3) receptors (A(3)R) is not known.
Methods And Results:
To test the hypothesis that A(1)R and A(3)R can protect the heart against systolic overload, we exposed A(3)R gene-deficient (A(3)R knockout [KO]) mice and A(1)R KO mice to transverse aortic constriction (TAC). Contrary to our hypothesis, A(3)R KO attenuated 5-week TAC-induced left ventricular hypertrophy (ratio of ventricular mass/body weight increased to 7.6+/-0.3 mg/g in wild-type mice compared with 6.3+/-0.4 mg/g in KO mice), fibrosis, and dysfunction (left ventricular ejection fraction decreased to 43+/-2.5% and 55+/-4.2% in wild-type and KO mice, respectively). A(3)R KO also attenuated the TAC-induced increases of myocardial atrial natriuretic peptide and the oxidative stress markers 3'-nitrotyrosine and 4-hydroxynonenal. In contrast, A(1)R KO increased TAC-induced mortality but did not alter ventricular hypertrophy or dysfunction compared with wild-type mice. In mice in which extracellular adenosine production was impaired by CD73 KO, TAC caused greater hypertrophy and dysfunction and increased myocardial 3'-nitrotyrosine. In neonatal rat cardiomyocytes induced to hypertrophy with phenylephrine, the adenosine analogue 2-chloroadenosine reduced cell area, protein synthesis, atrial natriuretic peptide, and 3'-nitrotyrosine. Antagonism of A(3)R significantly potentiated the antihypertrophic effects of 2-chloroadenosine.
Conclusions:
Adenosine exerts protective effects on the overloaded heart, but the A(3)R acts counter to the protective effect of adenosine. The data suggest that selective attenuation of A(3)R activity might be a novel approach to treat pressure overload-induced left ventricular hypertrophy and dysfunction.
Related Concept Videos
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Aortic Regurgitation III: Medical Management
Cardiopulmonary Resuscitation III: AED Use
Heart Failure II: Pathophysiology

